Receptor Tyrosine Kinase (RTK) (Panel I) Mutation PCR Array

qBiomarker Somatic Mutation PCR Array: Human Receptor Tyrosine Kinase (RTK) Pathways (Panel I) The Human Receptor Tyrosine Kinase (RTK) Pathways qBiomarker Somatic Mutation PCR Array is a translational research tool that allows rapid and accurate profiling of the somatic mutation status for the following receptor tyrosine kinase pathways: EGFR, ERBB2, PDGFR, FLT3, KIT, c-MET, FGFR2, and FGFR3. Panel I contains mutation assays for the receptor tyrosine kinases (RTKs). Components in the RTK pathways are frequently mutated in human cancers, and therefore warrant extensive investigation to enhance the understanding of carcinogenesis. The utility of individual and multiple somatic mutation status information in identifying key signaling transduction disruptions has been demonstrated in numerous research studies. For example, the mutation status of the EGFR and KRAS genes can predict the physiological response to certain drugs targeting these molecules. The RTK Pathways qBiomarker Somatic Mutation PCR Array, with its comprehensive content coverage, is designed for studying mutations in the context of these pathways and has the potential for discovering drug target biomarkers for a variety of human cancers involving these pathways and downstream effectors. Panel I includes 86 DNA sequence mutation assays designed to detect the most frequent, functionally verified, and biologically significant mutations in the RTKs. These mutations were chosen from curated, comprehensive somatic mutation databases and peerreviewed scientific literature. The simplicity of the product format and operating procedure allows routine somatic mutation profiling in any research laboratory with access to real-time PCR instruments. Panel I and Panel II are available in two separate 96-well format plates, or are available in a combined 384-well format (2 samples per plate). The qBiomarker Somatic Mutation PCR Arrays are intended for molecular biology applications. This product is not intended for the diagnosis, prevention, or treatment of a disease.

Assay Functional Annotations

How It Works

References

Resources

Modify this Array    EGFR gene: 21 mutation assays are included in this panel. These assays are able to detect the ~30 most frequently identified EGFR mutations including P-loop and activation loop point mutations, kinase domain deletion, and insertion mutations. ERBB2 gene: 4 mutation assays are included in this panel for the most frequently identified ERBB2 activating mutations. These mutations cluster in the ERBB2 kinase domain region. PDGFR-A gene: 12 mutation assays are included for PDGFR-A in this panel. These assays detect the most frequently identified PDGFR-A gain-of-function mutations, including deletion, point mutation, and deletion-insertion mutations in regions p.D842_S847, and p.R554_E571, and the point mutations p.N659Y and p.T674I. FLT3 gene: 4 mutation assays are included in this panel to cover the most frequently identified FLT3 mutations. These include point mutations and a deletion mutation in the activation loop portion of the sequence, and an insertion mutation in the juxtamembrane region of the coding sequence. KIT gene: 27 mutation assays are included for KIT in this panel. These assays detect the most frequently identified KIT gain-offunction mutations, such as the D816V point mutation, the exon 11 (juxtamembrane domain) deletion and point mutations, an exon 9 insertion mutation, and exon 13 point mutations. c-MET gene: The assays included in this panel detect the most frequently identified c-MET gain-of-function mutations, such as the tyrosine kinase domain and juxtamembrane domain point mutations. FGFR genes: 12 mutation assays are included for FGFR2 and FGFR33 in this panel. These assays detect the most frequently identified kinase domain mutations and non-kinase domain (e.g. extracellular domains such as the hinge region and IgG-like domain) mutations. Some of the somatic mutations included have congenital correlates that are involved in genetic diseases.

Assay Functional Annotations

How It Works

References

Resources

Overview of the qBiomarker Somatic Mutation PCR Array / Assay Protocol Overview of the qBiomarker Somatic Mutation PCR Array / Assay Protocol. The procedure involves DNA extraction (QIAGEN QIAamp DNA Mini Kit or FFPE Tissue Kit is recommended), an optional amplification (QIAGEN REPLI-g kit or REPLI-g UltraFast kit is recommended) step for DNA isolated from fresh samples, qPCR detection on qBiomarker Somatic Mutation PCR Arrays or Assays, and data analysis (using the qBiomarker Somatic Mutation Data Analysis Template). An optional DNA sample QC step immediately before the detection array or assay setup allows the user to qualify the DNA samples. Principle of Mutant Discrimination with ARMS® Back to Top

Assay Functional Annotations

How It Works

References

Resources

Back to Top

Assay Functional Annotations

How It Works

References

Resources

User Manual qBiomarker Somatic Mutation PCR Array System (PDF) Data Analysis qBiomarker Somatic Mutation PCR Array Data Analysis Software Application Data Detection Limits, Cancer Pathways FAQ Frequently Asked Questions about Somatic Mutation Assays and Arrays Webinar qBiomarker Somatic Mutation Analysis: Real-World Application Data Slide Presentation> Presentation about qBiomarker Somatic Mutation Assays and Arrays (PDF) Scientific Poster A Novel Tool for Pathway-Focused Cancer Mutation Profiling (PDF) Presented at American Association for Cancer Research 2011 White Paper Rapid and accurate cancer somatic mutation profiling with the qBiomarker Somatic Mutation PCR Array (PDF) Product Profile For screening biology-focused panels of gene mutations (PDF) Back to Top